AdvaMed 2015: Innovation Spotlight On Diabetes, Heart Failure Start-Ups
Executive Summary
Medtech start-ups continue to bring fresh ideas and new approaches to a market that is continually looking for better and cheaper treatment options. The device industry’s major trade association recently featured dozens of start-ups at its annual conference, and companies offering new solutions to battle chronic diseases were among the highlights.
You may also be interested in...
Diabetes Market Sees Advances In CGMs, Artificial Pancreas Systems, And Connectivity
The focus of the diabetes market is firmly on the development of an artificial pancreas, now within two or three years from becoming commercialized, and progress is going so well that several companies are in line to release a product. Meanwhile, digital health is increasingly playing a major role in diabetes care, and device manufacturers are investing in connectivity solutions to satisfy patient and consumer needs.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.